U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050056) titled 'Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC' on June 25.
Brief Summary: This study aims to explore the efficacy and safety of radiotherapy combined with immunotherapy in the neoadjuvant treatment of resectable NSCLC.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Resectable NSCLC
Intervention:
DRUG: Tislelizumab
200mg, iv, Q3W, 3-4 cycle
RADIATION: 3D-CRT/IMRT
40Gy in 20 fractions
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Northern Jiangsu People's Hospital
Information provided by (Responsible Party): Buhai Wang, Northern Jiangsu People's Hospital
Pub...